These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28344058)

  • 1. Possible Impact of Cytomegalovirus-Specific CD8
    Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation.
    Varanasi PR; Ogonek J; Luther S; Dammann E; Stadler M; Ganser A; Borchers S; Hambach L; Weissinger EM
    PLoS One; 2019; 14(3):e0213739. PubMed ID: 30889204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation.
    Ogonek J; Verma K; Schultze-Florey C; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Koehl U; Koenecke C; Weissinger EM; Hambach L
    J Immunol; 2017 Jul; 199(2):792-805. PubMed ID: 28630092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of recipient-derived as well as donor-derived clones of cytomegalovirus pp65-specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation.
    Terasako-Saito K; Nakasone H; Tanaka Y; Yamazaki R; Sato M; Sakamoto K; Ishihara Y; Kawamura K; Akahoshi Y; Hayakawa J; Wada H; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Ashizawa M; Kimura SI; Kikuchi M; Tanihara A; Kanda J; Kako S; Nishida J; Kanda Y
    Transpl Infect Dis; 2014 Dec; 16(6):930-40. PubMed ID: 25430567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution.
    van der Heiden P; Marijt E; Falkenburg F; Jedema I
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1776-1782. PubMed ID: 29626514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
    Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
    Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of recipient-derived antiviral T cells may influence donor chimerism after allogeneic stem cell transplantation.
    Borchers S; Weissinger EM; Pabst B; Ganzenmueller T; Dammann E; Luther S; Diedrich H; Ganser A; Stadler M
    Transpl Infect Dis; 2013 Dec; 15(6):627-33. PubMed ID: 23782397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
    van der Heiden PLJ; van Egmond HM; Veld SAJ; van de Meent M; Eefting M; de Wreede LC; Halkes CJM; Falkenburg JHF; Marijt WAF; Jedema I
    Transpl Immunol; 2018 Aug; 49():54-58. PubMed ID: 29679650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
    Koehl U; Dirkwinkel E; Koenig M; Erben S; Soerensen J; Bader P; Doerr HW; Preiser W; Weissinger E; Klingebiel T; Martin H; Lehrnbecher T
    Klin Padiatr; 2008; 220(6):348-52. PubMed ID: 18949669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.
    Borchers S; Bremm M; Lehrnbecher T; Dammann E; Pabst B; Wölk B; Esser R; Yildiz M; Eder M; Stadler M; Bader P; Martin H; Jarisch A; Schneider G; Klingebiel T; Ganser A; Weissinger EM; Koehl U
    PLoS One; 2012; 7(12):e50248. PubMed ID: 23272059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation.
    Foster AE; Gottlieb DJ; Sartor M; Hertzberg MS; Bradstock KF
    Biol Blood Marrow Transplant; 2002; 8(9):501-11. PubMed ID: 12374455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation.
    Kalra A; Williamson T; Daly A; Savoie ML; Stewart DA; Khan F; Storek J
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1654-1663. PubMed ID: 27246372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.